Summit Therapeutics Inc (NASDAQ:SMMT) has a beta value of -0.98 and has seen 3.38 million shares traded in the last trading session. The company, currently valued at $18.60B, closed the last trade at $25.22 per share which meant it gained $0.61 on the day or 2.48% during that session. The SMMT stock price is -34.38% off its 52-week high price of $33.89 and 91.67% above the 52-week low of $2.10. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.29 million shares traded. The 3-month trading volume is 2.94 million shares.
The consensus among analysts is that Summit Therapeutics Inc (SMMT) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.07.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Sporting 2.48% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SMMT stock price touched $25.22 or saw a rise of 3.85%. Year-to-date, Summit Therapeutics Inc shares have moved 41.33%, while the 5-day performance has seen it change 8.52%. Over the past 30 days, the shares of Summit Therapeutics Inc (NASDAQ:SMMT) have changed 29.73%. Short interest in the company has seen 23.77 million shares shorted with days to cover at 10.06.
Wall Street analysts have a consensus price target for the stock at $33.5, which means that the shares’ value could jump 24.72% from current levels. The projected low price target is $32.0 while the price target rests at a high of $35.0. In that case, then, we find that the current price level is -38.78% off the targeted high while a plunge would see the stock gain -26.88% from current levels.
Summit Therapeutics Inc (SMMT) estimates and forecasts
The company’s shares have gained 7.50% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.52% over the past 5 years. Earnings growth for 2025 is a modest -37.58% while over the next 5 years, the company’s earnings are expected to decrease by -28.26%.
SMMT Dividends
Summit Therapeutics Inc is expected to release its next earnings report on 2025-Feb-23 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Insiders own 84.36% of the company shares, while shares held by institutions stand at 12.92% with a share float percentage of 82.64%. Investors are also buoyed by the number of investors in a company, with Summit Therapeutics Inc having a total of 280.0 institutions that hold shares in the company. The top two institutional holders are BAKER BROS. ADVISORS LP with over 23.22 million shares worth more than $181.13 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 3.2804% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 8.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $68.78 million and represent 1.2457% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF . As of Dec 31, 2024 , the former fund manager holds about 0.46% shares in the company for having 3.4 shares of worth $85.87 million while later fund manager owns 3.32 shares of worth $83.74 million as of Feb 28, 2025 , which makes it owner of about 0.45% of company’s outstanding stock.
